A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets
Liu, S.; Chen, C.; Zhang, X.
Show abstract
Neoantigens are newly formed antigens generated by cancer cells but absent in normal cells. With their high specificity and immunogenicity characteristic, neoantigens are considered as an ideal target for immunotherapy. This study was aimed to investigate the signature of neoantigens in breast cancer. Somatic mutations, including SNVs and indels, were obtained from cBioPortal of 5991 breast cancer patients. For neoantigen prediction, 738 non-silent somatic variants present in at least 3 patients were selected., PIK3CA (38%), the highly mutated gene in breast cancer, can produce the highest number of neoantigens per gene. Some pan-cancer hotspot mutations, such as PIK3CA E545K (6.93%), can be recognized by at least one HLA molecule. Since there are more SNVs than indels in breast cancer, SNVs are the major source of neoantigens. Patients with hormone receptor positive or HER2 positive are more competent to produce neoantigens. Age, but not clinical stage, is a significant contributory factor of neoantigens production. We believe a detailed description of breast cancer neoantigens signatures could contribute to neoantigens based immunotherapy development.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.